Combination of radiotherapy with EGFR antagonists for head and neck carcinoma

International Journal of Clinical Oncology

Volumn 12, Issue 2, 2007, Pages 99-110

  Thariat, Juliette ^a   Yildirim, Gokcen ^a   Mason, Kathryn A ^a   Garden, Adam S ^a   Milas, Luka ^a   Ang, K Kian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Epidermal growth factor receptor (EGFR); Predictive molecular markers; Radiotherapy; Resistance; Targeted therapy

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTIBODY; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANERTINIB; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; HYDROXYUREA; LAPATINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; NUCLEOTIDE; PACLITAXEL; PANITUMUMAB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TAXANE DERIVATIVE; VANDETANIB;

CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DRUG FATALITY; DRUG MECHANISM; FEBRILE NEUTROPENIA; HEAD AND NECK CARCINOMA; HUMAN; LOADING DRUG DOSE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; RADIATION INJURY; RADIOSENSITIZATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 34247362063     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-006-0663-5     Document Type: Review

References (145)

1. A Jemal R Siegel E Ward 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130
2. F Robert MP Ezekiel SA Spencer 2001 Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J Clin Oncol 19 3234 3243
3. DO Schneider GF Whitmore 1963 Comparative effects of neutrons and X-rays on mammalian cells Radiat Res 18 286 306
4. JJ Kim IF Tannock 2005 Repopulation of cancer cells during therapy: an important cause of treatment failure Nat Rev Cancer 5 516 525
5. J Bourhis J Overgaard H Audry 2006 Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis Lancet 368 843 854
6. J Bourhis C Armand JP Pignon 2004 Update of MACH-NC (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 5505
7. M Al-Sarraf TF Pajak JS Cooper 1990 Chemo-radiotherapy in patients with locally advanced nasopharyngeal carcinoma: a Radiation Therapy Oncology Group study J Clin Oncol 8 1342 1351
8. S Cohen 1965 The stimulation of epidermal proliferation by a specific protein (EGF) Dev Biol 12 394 407
9. S Cohen G Carpenter 1975 Human epidermal growth factor: isolation and chemical and biological properties Proc Natl Acad Sci USA 72 1317 1321
10. S Cohen G Carpenter L King Jr 1980 Epidermal growth factor-receptor- protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity J Biol Chem 255 4834 4842
11. AW Burgess HS Cho C Eigenbrot 2003 An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors Mol Cell 12 541 552
12. SM Thomas FM Coppelli A Wells 2003 Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma Cancer Res 63 5629 5635
13. S Kalyankrishna JR Grandis 2006 Epidermal growth factor receptor biology in head and neck cancer J Clin Oncol 24 2666 2672
14. WX Schulze L Deng M Mann 2005 Phosphotyrosine interactome of the ErbB-receptor kinase family Mol Syst Biol 1 2005 0008
15. R Goldman RB Levy E Peles 1990 Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation Biochemistry 29 11024 11028
16. R Pinkas-Kramarski L Soussan H Waterman 1996 Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions EMBO J 15 2452 2467
17. Y Yarden 2001 The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities Eur J Cancer 37 Suppl 4 S3 S8
18. AP Gilmore AJ Valentijn P Wang 2002 Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor J Biol Chem 277 27643 27650
19. YN Kim P Dam PJ Bertics 2002 Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation Exp Cell Res 280 134 147
20. J Andreev ML Galisteo O Kranenburg 2001 Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade J Biol Chem 276 20130 20135
21. JE Darnell Jr IM Kerr GR Stark 1994 Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1415 1421
22. T Kijima H Niwa RA Steinman 2002 STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo Cell Growth Differ 13 355 362
23. S Xi Q Zhang WE Gooding 2003 Constitutive activation of Stat5b contributes to carcinogenesis in vivo Cancer Res 63 6763 6771
24. PM Harari S Huang 2006 Radiation combined with EGFR signal inhibitors: head and neck cancer focus Semin Radiat Oncol 16 38 44
25. NE Hynes HA Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 341 354
26. SY Lin K Makino W Xia 2001 Nuclear localization of EGF receptor and its potential new role as a transcription factor Nat Cell Biol 3 802 808
27. K Dittmann C Mayer B Fehrenbacher 2005 Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase J Biol Chem 280 31182 31189
28. HW Lo SC Hsu M Ali-Seyed 2005 Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway Cancer Cell 7 575 589
29. HW Lo MC Hung 2006 Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival Br J Cancer 94 184 188
30. N Hanada HW Lo CP Day 2006 Co-regulation of B-Myb expression by E2F1 and EGF receptor Mol Carcinog 45 10 17
31. KK Khanna SP Jackson 2001 DNA double-strand breaks: signaling, repair and the cancer connection Nat Genet 27 247 254
32. CM Warren R Landgraf 2006 Signaling through ERBB receptors: multiple layers of diversity and control Cell Signal 18 923 933
33. G Levkowitz H Waterman SA Ettenberg 1999 Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1 Mol Cell 4 1029 1040
34. HS Wiley 2003 Trafficking of the ErbB receptors and its influence on signaling Exp Cell Res 284 78 88
35. JL Boerner ML Demory C Silva 2004 Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II Mol Cell Biol 24 7059 7071
36. JR Grandis DJ Tweardy 1993 Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer Cancer Res 53 3579 3584
37. J Rubin Grandis MF Melhem EL Barnes 1996 Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck Cancer 78 1284 1292
38. DM Shin JY Ro WK Hong 1994 Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis Cancer Res 54 3153 3159
39. J Rubin Grandis Q Zeng DJ Tweardy 1996 Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines Nat Med 2 237 240
40. RK Schmidt-Ullrich RB Mikkelsen P Dent 1997 Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation Oncogene 15 1191 1197
41. JC Sok FM Coppelli SM Thomas 2006 Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting Clin Cancer Res 12 5064 5073
42. CJ Wikstrand RE McLendon AH Friedman 1997 Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII Cancer Res 57 4130 4140
43. TJ Lynch DW Bell R Sordella 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139
44. MC Etienne-Grimaldi S Pereira N Magne 2005 Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients Ann Oncol 16 934 941
45. F Cappuzzo M Varella-Garcia H Shigematsu 2005 Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients J Clin Oncol 23 5007 5018
46. A Psyrri Z Yu PM Weinberger 2005 Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis Clin Cancer Res 11 5856 5862
47. L Milas T Akimoto NR Hunter 2002 Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas Int J Radiat Oncol Biol Phys 52 514 521
48. HR Withers JM Taylor B Maciejewski 1988 The hazard of accelerated tumor clonogen repopulation during radiotherapy Acta Oncol 27 131 146
49. RK Schmidt-Ullrich K Valerie W Chan 1992 Expression of oestrogen receptor and transforming growth factor-alpha in MCF-7 cells after exposure to fractionated irradiation Int J Radiat Biol 61 405 415
50. BD Kavanagh PS Lin P Chen 1995 Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor Clin Cancer Res 1 1557 1562
51. RK Schmidt-Ullrich JN Contessa G Lammering 2003 ERBB receptor tyrosine kinases and cellular radiation responses Oncogene 22 5855 5865
52. T Akimoto NR Hunter L Buchmiller 1999 Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas Clin Cancer Res 5 2884 2890
53. KK Ang BA Berkey X Tu 2002 Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 7350 7356
54. K Liang KK Ang L Milas 2003 The epidermal growth factor receptor mediates radioresistance Int J Radiat Oncol Biol Phys 57 246 254
55. J Mendelsohn H Masui A Goldenberg 1987 Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway Trans Assoc Am Physicians 100 173 178
56. JD Sato T Kawamoto AD Le 1983 Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors Mol Biol Med 1 511 529
57. N Balaban J Moni M Shannon 1996 The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation Biochim Biophys Acta 1314 147 156
58. MN Saleh KP Raisch MA Stackhouse 1999 Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation Cancer Biother Radiopharm 14 451 463
59. SM Huang JM Bock PM Harari 1999 Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Res 59 1935 1940
60. SM Huang PM Harari 1999 Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results Invest New Drugs 17 259 269
61. L Milas K Mason N Hunter 2000 In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 701 708
62. S Nasu KK Ang Z Fan 2001 C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability Int J Radiat Oncol Biol Phys 51 474 477
63. C Bianco G Tortora R Bianco 2002 Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res 8 3250 3258
64. Y She F Lee J Chen 2003 The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index Clin Cancer Res 9 3773 3778
65. P Chinnaiyan S Huang G Vallabhaneni 2005 Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 3328 3335
66. B Solomon J Hagekyriakou MK Trivett 2003 EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma Int J Radiat Oncol Biol Phys 55 713 723
67. SM Huang PM Harari 2000 Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin Cancer Res 6 2166 2174
68. SM Huang J Li PM Harari 2002 Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade Mol Cancer Ther 1 507 514
69. M Baumann M Krause 2004 Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results Radiother Oncol 72 257 266
70. JA Bonner KP Raisch HQ Trummell 2000 Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers J Clin Oncol 18 47S 53S
71. EK Rowinsky 2004 The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors Annu Rev Med 55 433 457
72. S Li KR Schmitz PD Jeffrey 2005 Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 301 311
73. P Dent DB Reardon JS Park 1999 Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death Mol Biol Cell 10 2493 2506
74. JA Bonner PM Harari J Giralt 2006 Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 567 578
75. PM Harari GK Hartig 2003 Impact of the EGFR inhibitor C225 on wound healing in advanced head and neck cancer patients undergoing neck dissection J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22 220
76. JA Bonner J Giralt 2005 Improved preservation of larynx with the addition of cetuximab to radiation of cetuximab for cancers of the larynx and hypopharynx J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 23 5533
77. DG Pfister YB Su DH Kraus 2006 Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm J Clin Oncol 24 1072 1078
78. De La Garza JG, Granados M, Aguilar JL, et al. (2006) Phase II clinical trial preliminary report: Cetuximab, gemcitabine and simultaneous radiotherapy for locally advanced head and neck cancer: Preliminary report J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24:15 502
79. DT Chua JM Nicholls JS Sham 2004 Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy Int J Radiat Oncol Biol Phys 59 11 20
80. SM Bentzen BM Atasoy FM Daley 2005 Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial J Clin Oncol 23 5560 5567
81. JG Eriksen T Steiniche J Askaa 2004 The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck Int J Radiat Oncol Biol Phys 58 561 566
82. A Psyrri G Fountzilas 2006 Advances in the treatment of locally advanced non-nasopharyngeal squamous cell carcinoma of the head and neck region Med Oncol 23 1 15
83. B Burtness MA Goldwasser W Flood 2005 Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study J Clin Oncol 23 8646 8654
84. D Soulieres NN Senzer EE Vokes 2004 Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 77 85
85. L Saltz 2005 Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity? Clin Colorectal Cancer 5 Suppl 2 S98 S100
86. KY Chung J Shia NE Kemeny 2005 Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 1803 1810
87. R Dziadziuszko FR Hirsch M Varella-Garcia 2006 Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization - why, when, and how? Clin Cancer Res 12 4409s 4415s
88. J Loeffler-Ragg M Witsch-Baumgartner A Tzankov 2006 Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma Eur J Cancer 42 109 111
89. JS Lee JS Ro A Eisbruch 1988 Multiple restriction fragment length polymorphisms of the human epidermal growth factor receptor gene Cancer Res 48 4045 4048
90. EE Cohen F Rosen WM Stadler 2003 Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 1980 1987
91. TB Gibson A Ranganathan A Grothey 2006 Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer Clin Colorectal Cancer 6 29 31
92. J Baselga JM Trigo J Bourhis 2005 Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck J Clin Oncol 23 5568 5577
93. NW Choong EE Cohen 2006 Epidermal growth factor receptor directed therapy in head and neck cancer Crit Rev Oncol Hematol 57 25 43
94. L Milas F Fang KA Mason 2007 Importance of maintenance therapy in C225-induced enhancement of tumor control by fractionated radiation Int J Radiat Oncol Biol Phys 1 67 568 572
95. T Crombet M Osorio T Cruz 2004 Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients J Clin Oncol 22 1646 1654
96. DH Lynch XD Yang 2002 Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment Semin Oncol 29 47 50
97. EE Cohen 2006 Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 24 2659 2665
98. D Herchenhorn FL Dias CG Ferreira 2006 Phase I/II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 5575
99. P Savvides SS Agarwala J Greskovich 2006 Phase I study of the EGFR tyrosine kinase inhibitor erlotinib in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN) J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 5545
100. CT Allen EA Donovan Z Chen 2006 Clinical, signaling pathway, and cellular effects of epidermal growth factor receptor (EGFR) inhibition with gefitinib in combination with paclitaxel and radiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 15540
101. HH Doss FA Greco AA Meluch 2006 Induction chemotherapy + gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients (pts) with locally advanced squamous carcinoma of the head and neck: A phase I/II trial of the Minnie Pearl Cancer Research Network J Clin Oncol ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 5543
102. TS Lawrence MK Nyati 2002 Small-molecule tyrosine kinase inhibitors as radiosensitizers Semin Radiat Oncol 12 33 36
103. MK Nyati D Maheshwari S Hanasoge 2004 Radiosensitization by pan ErbB inhibitor CI-1033 in vitro and in vivo Clin Cancer Res 10 691 700
104. MR Dewji 2004 Early phase I data on an irreversible pan-erb inhibitor: CI-1033. What did we learn? J Chemother 16 Suppl 4 44 48
105. E Calvo AW Tolcher LA Hammond 2004 Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study Clin Cancer Res 10 7112 7120
106. J Nemunaitis I Eiseman C Cunningham 2005 Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer Clin Cancer Res 11 3846 3853
107. S Campos O Hamid MV Seiden 2005 Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer J Clin Oncol 23 5597 5604
108. LL Garland M Hidalgo DS Mendelson 2006 A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors Clin Cancer Res 12 4274 4282
109. ER Wood AT Truesdale OB McDonald 2004 A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res 64 6652 6659
110. Harrington K, Bourhis J, Nutting CM, et al. (2006) A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
111. P Matar F Rojo R Cassia 2004 Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting Clin Cancer Res 10 6487 6501
112. S Huang EA Armstrong S Benavente 2004 Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor Cancer Res 64 5355 5362
113. J Baselga P Schöffski F Rojo 2006 A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC) J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 3006
114. D Lee 2005 Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer Clin Lung Cancer 7 89 91
115. MW Pedersen M Meltorn L Damstrup 2001 The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy Ann Oncol 12 745 760
116. G Lammering TH Hewit K Valerie 2003 EGFRvIII-mediated radioresistance through a strong cytoprotective response Oncogene 22 5545 5553
117. M Zhan ZC Han 2004 Phosphatidylinositide 3-kinase/AKT in radiation responses Histol Histopathol 19 915 923
118. JM Pedrero DG Carracedo CM Pinto 2005 Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma Int J Cancer 114 242 248
119. K Okami L Wu G Riggins 1998 Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors Cancer Res 58 509 511
120. AB Motoyama NE Hynes HA Lane 2002 The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides Cancer Res 62 3151 3158
121. A Hurbin L Dubrez JL Coll 2002 Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines J Biol Chem 277 49127 49133
122. A Chakravarti JS Loeffler NJ Dyson 2002 Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling Cancer Res 62 200 207
123. H Daub FU Weiss C Wallasch 1996 Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors Nature 379 557 560
124. S Thomas AQZ Wentzel 2005 Prostaglandin E2 and bradykinin contribute to head and neck squamous cell carcinoma carcinogenesis via EGFR dependent and independent mechanisms Proc Am Assoc Cancer Res 46 169
125. S Hart OM Fischer N Prenzel 2005 GPCR-induced migration of breast carcinoma cells depends on both EGFR signal transactivation and EGFR-independent pathways Biol Chem 386 845 855
126. K Krysan KL Reckamp H Dalwadi 2005 Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner Cancer Res 65 6275 6281
127. G Bowers D Reardon T Hewitt 2001 The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells Oncogene 20 1388 1397
128. C Wild-Bode M Weller A Rimner 2001 Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma Cancer Res 61 2744 2750
129. RJ Eisma JD Spiro DL Kreutzer 1997 Vascular endothelial growth factor expression in head and neck squamous cell carcinoma Am J Surg 174 513 517
130. A Viloria-Petit T Crombet S Jothy 2001 Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis Cancer Res 61 5090 5101
131. Y Lu X Zi Y Zhao 2001 Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) J Natl Cancer Inst 93 1852 1857
132. JR Tonra DS Deevi E Corcoran 2006 Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy Clin Cancer Res 12 2197 2207
133. P Traxler PR Allegrini R Brandt 2004 AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity Cancer Res 64 4931 4941
134. LF Hennequin AP Thomas C Johnstone 1999 Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors J Med Chem 42 5369 5389
135. OG Yigitbasi MN Younes D Doan 2004 Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade Cancer Res 64 7977 7984
136. SR Wedge DJ Ogilvie M Dukes 2002 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration Cancer Res 62 4645 4655
137. F Ciardiello R Caputo V Damiano 2003 Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase Clin Cancer Res 9 1546 1556
138. KJ Williams BA Telfer S Brave 2004 ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity Clin Cancer Res 10 8587 8593
139. MP Morelli T Cascone T Troiani 2006 Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases J Cell Physiol 208 344 353
140. WD Brazelle W Shi DW Siemann 2006 VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy Int J Radiat Oncol Biol Phys 65 836 841
141. EL Kwak R Sordella DW Bell 2005 Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci USA 102 7665 7670
142. MP Morelli T Cascone T Troiani 2006 Antitumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 131
143. JV Heymach 2005 ZD6474-clinical experience to date Br J Cancer 92 Suppl 1 S14 20
144. SN Holden SG Eckhardt R Basser 2005 Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors Ann Oncol 16 1391 1397
145. SK Williamson J Moon CH Huang 2006 A phase II trial of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial J Clin Oncol. ASCO Annual Meeting Proceedings (Post-Meeting Edition) 24 5550